DeepMed Research

ENZON PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1981-01-01

Employees: 1

Market Cap: -

Website: http://www.enzon.com

Clinical Trials

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

Phase 1

Suspended

Conditions: Prostatic Neoplasm

Interventions: Drug: EZN-4176

First Posted Date: 2011-04-19

Last Posted Date: 2012-12-18

Lead Sponsor: Enzon Pharmaceuticals, Inc.

Target Recruit Count: 150

Registration Number: NCT01337518

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇬🇧
Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom

Study of EZN-2208 Pediatric Patients With Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: EZN-2208

First Posted Date: 2011-02-14

Last Posted Date: 2022-02-14

Lead Sponsor: Enzon Pharmaceuticals, Inc.

Target Recruit Count: 32

Registration Number: NCT01295697

Locations: 🇺🇸
Lia Gore, MD, Aurora, Colorado, United States
🇺🇸
Suzanne Shusterman, MD, Boston, Massachusetts, United States
🇺🇸
Rochelle Bagatell, MD (Principal Investigator), Philadelphia, Pennsylvania, United States

and more 1 locations

A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: EZN-2208

First Posted Date: 2009-12-21

Last Posted Date: 2022-02-14

Lead Sponsor: Enzon Pharmaceuticals, Inc.

Target Recruit Count: 160

Registration Number: NCT01036113

Locations: 🇺🇸
Location #41, Columbus, Ohio, United States
🇺🇸
Location #32, Murrieta, California, United States
🇺🇸
Location #21, Salem, Virginia, United States

and more 33 locations

A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: EZN-2208, Cetuximab and Irinotecan

First Posted Date: 2009-07-02

Last Posted Date: 2011-09-20

Lead Sponsor: Enzon Pharmaceuticals, Inc.

Target Recruit Count: 220

Registration Number: NCT00931840

Locations: 🇺🇸
Location# 008, Columbus, Ohio, United States
🇨🇦
Location # 079, Toronto, Ontario, Canada
🇬🇧
Location # 083, London, England, United Kingdom

and more 57 locations

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

Phase 1

Withdrawn

Conditions: Infection
Lymphoma
Myelodysplastic Syndromes
Neutropenia
Unspecified Childhood Solid Tumor, Protocol Specific
Leukemia
Fever, Sweats, and Hot Flashes

First Posted Date: 2009-04-23

Last Posted Date: 2012-06-20

Lead Sponsor: Enzon Pharmaceuticals, Inc.

Registration Number: NCT00886496

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)

Phase 1

Completed

Conditions: Lymphoma
Advanced Solid Tumors

First Posted Date: 2007-08-24

Last Posted Date: 2010-04-02

Lead Sponsor: Enzon Pharmaceuticals, Inc.

Target Recruit Count: 34

Registration Number: NCT00520390

Locations: 🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States

A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia

Phase 1

Withdrawn

Conditions: Cancer
Hematologic Diseases
Fever
Neutropenia

Interventions: Drug: Intravenous recombinant human mannose binding lectin

First Posted Date: 2007-08-24

Last Posted Date: 2012-09-05

Lead Sponsor: Enzon Pharmaceuticals, Inc.

Registration Number: NCT00520325

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)

Phase 1

Completed

Conditions: Advanced Solid Tumors
Lymphoma

First Posted Date: 2007-08-24

Last Posted Date: 2009-10-09

Lead Sponsor: Enzon Pharmaceuticals, Inc.

Target Recruit Count: 34

Registration Number: NCT00520637

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology, Chicago, Illinois, United States

Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Carcinoma
Lymphoma

First Posted Date: 2007-04-27

Last Posted Date: 2011-07-07

Lead Sponsor: Enzon Pharmaceuticals, Inc.

Target Recruit Count: 52

Registration Number: NCT00466583

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Multicenter Study Evaluating the Safety and Tolerability of Intravenous rhMBL in Liver Transplant Recipients.

Phase 1

Terminated

Conditions: Liver Transplantation

Interventions: Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)

First Posted Date: 2006-12-22

Last Posted Date: 2011-08-09

Lead Sponsor: Enzon Pharmaceuticals, Inc.

Target Recruit Count: 24

Registration Number: NCT00415311

Locations: 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
🇺🇸
Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy